02/27/2026
In this article, researchers explore why some patients become resistant to BCG, the gold‑standard treatment for high‑risk non–muscle‑invasive bladder cancer, and how emerging combination therapies may boost effectiveness, reduce side effects, and preserve the bladder. The review highlights promising chemo‑ and immunotherapy pairings, the lingering impact of BCG shortages, and the need for long‑term trials to guide safer, more durable treatment options.
🔗 Click to read more: https://bit.ly/4rFFWUa